Serious adverse events by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in adverse events: grades 3 and 4 by day 30 compared with placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events (day 7 to day 30 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review
Adverse events · neonates with fast breathing alone
1 finding from 1 review
Adverse events · neonates with possible serious bacterial infection
Comparison 2: 7 days oral amoxicillin + injectable gentamicin showed no clear difference in adverse events compared with 7 days injectable benzylpenicillin + injectable gentamicin (moderate certainty).
1 finding from 1 review
Adverse events · neonates with possible serious bacterial infection
1 finding from 1 review
Adverse events · neonates with possible serious bacterial infection
Comparison 2: 2 days injectable benzylpenicillin + injectable… showed no clear difference in adverse events compared with 7 days injectable benzylpenicillin + injectable gentamicin (moderate certainty).
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Severe adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes serious adverse events compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
1 finding from 1 review
OR 1 [0.68, 1.46]
Studies not reported
Low
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 0.83 [0.37, 1.86]
Studies not reported
Moderate
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.92 [0.63, 1.33]
Studies not reported
High